Leukocytosis, JAK2V617F Mutation, and Hemostasis in Myeloproliferative Disorders

 https://www.karger.com/Article/Abstract/175153


Pathophysiology of Haemostasis and Thrombosis

 

Leukocytosis, JAK2V617F Mutation, and Hemostasis in Myeloproliferative Disorders

Marchetti M.a, b · Falanga A.b

Author affiliations

Keywords: Cytoreductive therapyEssential thrombocythemiaMyeloproliferative disordersHemostatic system activationJAK2V617F mutationLeukocytosisPolycythemia vera

Pathophysiol Haemos Thromb 2007–08;36:148–159
https://doi.org/10.1159/000175153

Abstract

Thrombosis is a leading cause of morbidity and mortality in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Several mechanisms have been proposed to cause or to contribute to the acquired thrombophilic state of these patients, including platelet and red blood cell abnormalities. The increase in white blood cell count, found in most subjects with these disorders, raises the possibility that circulating leukocytes may represent another prothrombotic factor, as demonstrated for other conditions, including sickle cell, coronary heart, and peripheral arterial diseases. Published data demonstrate that neutrophil activation occurs in ET and PV patients in parallel with the appearance of laboratory signs of hemostatic system activation, suggesting an involvement of these cells in the pathogenesis of the thrombotic predisposition of these subjects. In 2005, an acquired point mutation in the pseudokinase domain of Janus kinase 2 (JAK2V617F) has been described in these disorders, and has attracted an enormous interest both as a diagnostic and prognostic tool, and as a potential therapeutic target. Retrospective data have identified JAK2V617F as a risk factor for thrombosis in ET, and have also shown a close association with abdominal vein thrombosis. JAK2V617F is variably associated with thrombosis and, more consistently, with elevations in blood cell counts. A clear link appears to exist between leukocytosis, JAK2V617F, and the hemostatic system activation in patients with Bcl-negative myeloproliferative disorders.

© 2009 S. Karger AG, Basel



Related Articles:

Journal LogoActa Haematol 2015;133:36-51Changing Concepts of Diagnostic Criteria of Myeloproliferative Disorders and the Molecular Etiology and...Michiels J.J., Berneman Z., Schroyens W., De Raeve H. et al.The Polycythemia Vera Study Group (PVSG) and WHO classifications distinguished the Philadelphia (Ph1) chromosome-positive chronic myeloid leukemia from the Ph1-negative myeloproliferative...Go to Article
Journal LogoPathophysiol Haemos Thromb 2009–10;37:247–288Posters. pp 247–288Go to Article

References

  1. Gruppo Italiano Studio Policitemia: Polycythemia vera: the natural history of 1,213 patients followed for 20 years. Ann Intern Med 1995;123:656–664.
    External Resources
  2. Elliott MA, Tefferi A: Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275–290.
    External Resources
  3. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W: Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006;32:174–207.
    External Resources
  4. Barbui T, Finazzi G: Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 2007;33:321–329.
    External Resources
  5. Coller BS: Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol 2005;25:658–670.
    External Resources
  6. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477–1482.
    External Resources
  7. Landolfi R, Di Gennaro L, Barbui T, et al: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446–2452.
    External Resources
  8. Carobbio A, Finazzi G, Guerini V, et al: Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status. Blood 2007;109:2310–2313.
    External Resources
  9. Carobbio A, Antonioli E, Guglielmelli P, et al: Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;26:2732–2736.
    External Resources
  10. De Stefano V, Za T, Rossi E, et al: Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008;93:372–380.
    External Resources
  11. Carobbio A, Finazzi G, Antonioli E, et al: Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008;112:3135–3137.
    External Resources
  12. Lowe GD: Common risk factors for both arterial and venous thrombosis. Br J Haematol 2008;140:488–495.
    External Resources
  13. Agnelli G, Becattini C: Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost 2006;4:1886–1890.
    External Resources
  14. Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Marziali S, Barbui T: Hemostatic system activation in patients with lupus anticoagulant and essential thrombocythemia. Semin Thromb Hemost 1994;20:324–327.
    External Resources
  15. Falanga A, Marchetti M, Evangelista V, et al: Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261–4266.
    External Resources
  16. Wieczorek I, MacGregor IR, Ludlam CA: Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia. Am J Hematol 1995;49:277–281.
    External Resources
  17. Posan E, Ujj G, Kiss A, Telek B, Rak K, Udvardy M: Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia. Thromb Res 1998;90:51–56.
    External Resources
  18. Cortelazzo S, Marchetti M, Orlando E, Falanga A, Barbui T, Buchanan MR: Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. Am J Hematol 1998;57:277–282.
    External Resources
  19. Wheeler JG, Mussolino ME, Gillum RF, Danesh J: Associations between differential leucocyte count and incident coronary heart disease: 1,764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J 2004;25:1287–1292.
    External Resources
  20. Naruko T, Ueda M, Haze K, et al: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106:2894–2900.
    External Resources
  21. Falanga A, Marchetti M, Barbui T, Smith CW: Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 2005;42:239–247.
    External Resources
  22. Afshar-Kharghan V, Thiagarajan P: Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006;13:34–39.
    External Resources
  23. Stief TW: Regulation of hemostasis by singlet oxygen (1ΔO2*). Curr Vasc Pharmacol 2004;2:357–362.
    External Resources
  24. Vischer UM, Jornot L, Wollheim CB, Theler JM: Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. Blood 1995;85:3164–3172.
    External Resources
  25. Camire RM, Kalafatis M, Tracy PB: Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding. Biochemistry 1998;37:11896–11906.
    External Resources
  26. Plescia J, Altieri DC: Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J 1996;319:873–879.
    External Resources
  27. Evangelista V, Piccardoni P, White JG, de Gaetano G, Cerletti C: Cathepsin G-dependent platelet stimulation by activated polymorphonuclear leukocytes and its inhibition by antiproteinases: role of P-selectin-mediated cell-cell adhesion. Blood 1993;81:2947–2957.
    External Resources
  28. Nemerson Y: Tissue factor in neutrophils. Thromb Haemost 2000;83:802.
    External Resources
  29. Giesen PL, Rauch U, Bohrmann B, et al: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311–2315.
    External Resources
  30. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA: The neutrophil as a cellular source of chemokines. Immunol Rev 2000;177:195–203.
    External Resources
  31. Celi A, Pellegrini G, Lorenzet R, et al: P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994;91:8767–8771.
    External Resources
  32. De Gaetano G, Cerletti C, Evangelista V: Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis 1999;29:41–49.
    External Resources
  33. Harlan JM, Killen PD, Harker LA, Striker GE, Wright DG: Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest 1981;68:1394–1403.
    External Resources
  34. Kolpakov V, D’Adamo MC, Salvatore L, et al: Neutrophil derived cathepsin G induces potentially thrombogenic changes in human endothelial cells: a scanning electron microscopy study in static and dynamic conditions. Thromb Haemost 1994;72:140–145.
    External Resources
  35. Falanga A, Marchetti M, Evangelista V, et al: Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999;93:2506–2514.
    External Resources
  36. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T: Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523–530.
    External Resources
  37. Higuchi DA, Wun TC, Likert KM, Broze GJ Jr: The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992;79:1712–1719.
    External Resources
  38. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC: Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66:143–151.
    External Resources
  39. Alvarez-Larran A, Garcia-Pagan JC, Abraldes JG, et al: Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 2004;124:329–335.
    External Resources
  40. Villmow T, Kemkes-Matthes B, Matzdorff AC: Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002;108:139–145.
    External Resources
  41. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
    External Resources
  42. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387–397.
    External Resources
  43. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
    External Resources
  44. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
    External Resources
  45. Dupont S, Masse A, James C, et al: The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007;110:1013–1021.
    External Resources
  46. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL: JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006;108:1652–1660.
    External Resources
  47. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG: Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274–4281.
    External Resources
  48. Vannucchi AM, Antonioli E, Guglielmelli P, et al: Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007;110:840–846.
    External Resources
  49. Moliterno AR, Williams DM, Rogers O, Spivak JL: Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006;108:3913–3915.
    External Resources
  50. Antonioli E, Guglielmelli P, Poli G, et al: Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008;93:41–48.
    External Resources
  51. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC: The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis – impact on disease phenotype. Eur J Haematol 2007;79:508–515.
    External Resources
  52. Campbell PJ, Scott LM, Buck G, et al: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945–1953.
    External Resources
  53. Passamonti F, Randi ML, Rumi E, et al: Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 2007;110:485–489.
    External Resources
  54. Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T: Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007;92:135–136.
    External Resources
  55. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C: The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006;132:244–245.
    External Resources
  56. De Stefano V, Fiorini A, Rossi E, et al: Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708–714.
    External Resources
  57. Robertson B, Urquhart C, Ford I, et al: Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007;5:1679–1685.
    External Resources
  58. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F: Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169–175.
    External Resources
  59. Falanga A, Marchetti M, Vignoli A, et al: V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007;35:702–711.
    External Resources
  60. Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, et al: Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol 2008;87:269–276.
    External Resources
  61. Muller I, Klocke A, Alex M, et al: Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003;17:476–478.
    External Resources
  62. Falati S, Liu Q, Gross P, et al: Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585–1598.
    External Resources
  63. Myers DD, Hawley AE, Farris DM, et al: P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003;38:1075–1089.
    External Resources
  64. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY: Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004;110:1794–1798.
    External Resources
  65. Rafail S, Ritis K, Schaefer K, et al: Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-dependent mechanisms and TNF-α involvement. Thromb Res 2008;122:366–375.
    External Resources
  66. Marchetti M, Castoldi E, Spronk H, et al: Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008 (in press).
  67. Cortelazzo S, Finazzi G, Ruggeri M, et al: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132–1136.
    External Resources
  68. Harrison CN, Campbell PJ, Buck G, et al: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33–45.
    External Resources
  69. Maugeri N, Giordano G, Petrilli MP, et al: Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006;4:2593–2598.
    External Resources
  70. Ricksten A, Palmqvist L, Johansson P, Andreasson B: Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008;93:1260–1261.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Paper


https://www.karger.com/Article/Abstract/175153

at

Nessun commento:

Posta un commento

Iscriviti a: Commenti sul post (Atom)

Lettera aperta al signor Luigi di Maio, deputato del Popolo Italiano

ZZZ, 04.07.2020 C.A. deputato Luigi di Maio sia nella sua funzione di deputato sia nella sua funzione di ministro degli esteri ...